New Viral Vector Strategy Targets Brain Cancer

Siren Biotechnology receives the first FDA clearance for an AAV-based cancer trial, targeting aggressive glioblastoma with a viral vector approach

16 Mar 2026

Gene therapy has reached a new frontier in oncology. Siren Biotechnology recently became the first company to receive clearance from the Food and Drug Administration for a clinical trial using an adeno-associated virus, or AAV, to treat a cancer indication. The move marks a significant expansion of viral vector technology, which has primarily been used to treat rare genetic diseases, into the challenging field of solid tumor oncology.

The San Francisco-based company’s lead program, SRN-101, targets recurrent high-grade glioma, an aggressive form of brain cancer with few effective treatment options once it returns. After clearing the company’s investigational new drug application in January 2026, the F.D.A. granted the therapy a fast-track designation in February. The designation formally recognizes the potential of the treatment to address a serious and underserved medical need, a status often used to accelerate the development of promising clinical candidates.

The therapy utilizes a recombinant AAV vector to deliver an engineered, immune-stimulating cytokine directly into the tumor microenvironment. Analysts noted that by concentrating immune activation at the site of the malignancy, the approach seeks to avoid the complications of systemic treatments that can overwhelm the body. This targeted delivery strategy is designed to overcome the immunosuppressive environment of glioblastomas, which has historically neutralized checkpoint inhibitors and other immunotherapies that have seen success in different cancer types.

“Fast-track designation underscores the urgency of bringing new therapeutic options to patients,” said Nicole K. Paulk, the founder and chief executive of Siren Biotechnology. Supported in part by the California Institute for Regenerative Medicine, the company intends to advance the first-in-human trial before potentially extending its platform to other solid tumors. Still, the transition from rare disease applications to oncology remains a steep technical climb, and the durability of the immune response in a clinical setting remains to be proven.

For the biotechnology industry, the milestone suggests a maturing of gene therapy platforms. While AAV technology has already been validated in treatments for hemophilia and spinal muscular atrophy, its application in oncology represents a shift toward engineering the immune system to recognize and destroy tumors. The results of the upcoming study are expected to provide the first clear evidence of whether these viral vectors can be deployed effectively against solid tumors at scale.